๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The diagnosis of eating disorders in adults with learning disabilities: Conceptualisation and implications for clinical practice

โœ Scribed by Ceri J. Jones; Judith Samuel


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
146 KB
Volume
18
Category
Article
ISSN
1072-4133

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Economic Implications of the Use of Anti
โœ S. BHAUMIK; C. DUGGIRALA; J. BEE; H. WILDGUST ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 104 KB ๐Ÿ‘ 2 views

The cost of treatment with TCAs and SSRIs were audited over a 9-month period in patients with major depression and co-morbid learning disabilities, using retrospective case-note analysis. Drug costs per treatment episode were found to be least for TCAs whilst they also incurred the highest side-eect

A naturalistic study in the use of antid
โœ S. Bhaumik; R. A. Collacott; D. Gandhi; C. Duggirala; H. J. Wildgust ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 475 KB

Very few studies have been undertaken looking at the use of anti-depressants in adults with learning disabilities and, more recently, with the advent of SSRIs there has not been any study comparing the use of SSRIs with tricyclic drugs in this group. A naturalistic study involving adults with learni

Classification and diagnosis of the anxi
โœ Martin Roth; Christopher Mountjoy ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 173 KB ๐Ÿ‘ 2 views

145 patients diagnosed with a structured interview as `depressive illness' or `anxiety disorder' were submitted to multivariate analyses which yielded a bimodal distribution corresponding to the anxiety and depressive disorders, respectively. As anxiety and depressive proยฎles were negatively correla

Review of donepezil, rivastigmine, galan
โœ V. P. Prasher ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 1 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of antiโ€dementia drugs. However, there is limited information available regarding the bioโ€medical aspects of the differing drugs; particularly relating to adults with intellectual disability